Pasar al contenido principal

DESARROLLO DE NUEVAS ESTRATEGIAS PARA MEJORAR LAS TERAPIAS DIRIGIDAS DEL COLANGIOCARCINOMA

PID2023-146827OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts

  • Amengual, Josep
  • Gonzalez-Sanchez, Ester
  • Yáñez-Bartolome, Mariana
  • Sererols-Viñas, Laura
  • Ravichandran, Sriram
  • Guiton, Celia
  • Fuste, Noel P.
  • Alay, Ania
  • Hijazo-Pechero, Sara
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Cantos-Cortes, Ana
  • Espinosa-Sotelo, Rut
  • Ramos, Emilio
  • Serrano, Teresa
  • Calvo, Mariona
  • Laquente, Berta
  • Ferrer, Joana
  • Pons, Gabriel
  • Mendez-Lucas, Andrés
  • Dooley, Steven
  • Ilyas, Sumera I.
  • Vallette, Marie
  • Aoudjehane, Lynda
  • Lequoy, Marie
  • Fouassier, Laura
  • Coulouarn, Cédric
  • Affò, Silvia
  • Scheiter, Alexander
  • Calvisi, Diego F.
  • Tian, Tian V.
  • Fabregat, Isabel
  • Vaquero, Javier
Transforming growth factor beta (TGF-β) signalling has become an attractive therapeutic target due to its pro-tumorigenic actions on epithelial cells and its immunosuppressive effects in the tumour microenvironment. In intrahepatic cholangiocarcinoma (iCCA), a highly aggressive malignancy of the biliary tract with poor prognosis, the latest clinical trials using TGF-β inhibitors have failed indicating that the specific actions carried out by TGF-β in iCCA are yet not well delineated. Here, we show that TGF-β signalling is highly active in iCCA and exerts a prominent suppressor effect on tumour cell lines and organoids established from iCCA metastases biopsies, that relies on a functional canonical SMAD2/3/4 signalling. Thus, TGF-β inhibitors promote, instead of inhibiting, tumour cell growth. In this context, a promising strategy is to target intracellular proteins downstream the TGF-β receptors accounting only for TGF-β pro-tumorigenic actions. NADPH oxidase 4 (NOX4), a downstream mediator of the TGF-β signalling pathway, is strictly expressed in cancer-associated fibroblasts (CAF) of iCCA and acts in concert with NOX1 to regulate CAF functions. Use of a dual NOX4/NOX1 inhibitor impaired CAF actions and reduced tumour growth in vitro and in two different in vivo iCCA experimental models. Collectively, our findings reveal an actionable way to specifically target TGF-β pro-tumorigenic actions in CAF from iCCA without undesirable side effects on tumour cells, suggesting a potentially bright future for dual NOX4/NOX1 inhibitors in the clinics, alone or in combination with other therapies., This work was supported by (i) Spanish Association for Cancer Research (AECC), Spain, grant #PRYGN211279FABR, to I.F.; (ii) Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers #RTI2018-094079-B-100, #RTC2019-007125-1, to I.F.; #PID2019-108651RJ-I00, PID2022-141984OB-I00 and RYC2021-034121-I, to J.V. J.V. was funded by AEI, MICIN, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and “Ramon y Cajal” program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. C.C. is supported by Inserm, Université de Rennes, Ligue Contre le Cancer (R23037NN), INCa (EU TRANSCAN23-002-2023-129, INCa_18688, R21251ND), ITMO Cancer of AVIESAN within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm (C18007NS, C20013NS, C20014NS), the French Ministry of Health and the French National Cancer Institute (PRT-K20-136). T.V.T. was supported by grants from the Spanish Ministry of Science, Innovation and University (PID2019-108008RJ-I00, PID2023-146827OB-I00), Fundació La Marató TV3 (201931-31), and “Ramon y Cajal” program (RYC2020-029098-I). L.F. received financial support from the “Ligue contre le cancer” (RS24/75-62) and from ITMO Cancer of Aviesan on funds administered by Inserm (C21044DS/ ASC21044DSA). S.A. is supported by PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312* and Ramon y Cajal program RYC2022-036321-I. *, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe

  • Boilève, Alice
  • Turpin, Anthony
  • TIAN, TIAN
  • Neuzillet, Cindy
Biliary tract cancers: Disparities; Healthcare, Cánceres de las vías biliares: Disparidades; Atención sanitaria, Càncers de les vies biliars; Disparitats; Atenció sanitària, TVT is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, and Fundación AstraZeneca.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

  • Llorente, Sofía
  • TIAN, TIAN
  • Lamarca, Angela
Neuregulin 1 fusions; Solid tumors, Fusiones de neuregulina; Tumores sólidos, Fusions de neuregulina; Tumors sòlids, S.L. is supported by AGAUR-FI Joan Oró fellowship (2024 FI-1 00399) from the Generalitat de Catalunya. A.L. is supported by grants from the Fundación AstraZeneca “Jóvenes Investigadores” program. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe

  • Boilève, Alice
  • Turpin, Anthony
  • TIAN, TIAN
  • Neuzillet, Cindy
Biliary tract cancers: Disparities; Healthcare, Cánceres de las vías biliares: Disparidades; Atención sanitaria, Càncers de les vies biliars; Disparitats; Atenció sanitària, TVT is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, and Fundación AstraZeneca.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

  • Llorente, Sofía
  • TIAN, TIAN
  • Lamarca, Angela
Neuregulin 1 fusions; Solid tumors, Fusiones de neuregulina; Tumores sólidos, Fusions de neuregulina; Tumors sòlids, S.L. is supported by AGAUR-FI Joan Oró fellowship (2024 FI-1 00399) from the Generalitat de Catalunya. A.L. is supported by grants from the Fundación AstraZeneca “Jóvenes Investigadores” program. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.